SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

AbbVie’s atogepant meets late-stage goal in menstrual migraine study

AbbVie said its migraine treatment atogepant, branded as Qulipta in the U.S., reduced migraine days associated with the menstrual period in a late-stage study.

ABBV

AbbVie said on Thursday that its migraine drug reduced migraine days linked to the menstrual period in a late-stage study. The treatment, chemically known as atogepant, is approved in the U.S. as Qulipta for migraine prevention in adults. The source text is truncated after stating that the drug met t…

Related stories